Literature DB >> 3739899

The triglyceride issue: a view from Framingham.

W P Castelli.   

Abstract

Triglycerides make up the overwhelming proportion of dietary fat consumed in the United States and other industrialized nations. Triglyceride elevation is directly associated with relative weight and age in both sexes, oral contraceptive use in women, and the development of diabetes mellitus. Triglyceride elevations are a highly significant independent risk factor for coronary heart disease (CHD) in women. They appear to be important in men with low high-density lipoprotein (HDL) cholesterol (less than 40 ml/dl). Dangerously high levels of triglyceride are associated with a high total cholesterol/HDL cholesterol ratio, which is an excellent indicator of CHD risk in both sexes. Individuals with elevated triglycerides should be considered at risk for CHD unless the total cholesterol/HDL cholesterol ratio is under 3.5. In practice, however, only about 10% of individuals with elevated triglycerides prove to have such low total cholesterol/HDL cholesterol ratios.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3739899     DOI: 10.1016/0002-8703(86)90296-6

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  76 in total

1.  Topical timolol and serum lipoproteins.

Authors:  J West; S Longstaff
Journal:  Br J Ophthalmol       Date:  1990-11       Impact factor: 4.638

2.  The distribution profiles of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patients.

Authors:  R W James; D Pometta
Journal:  Diabetologia       Date:  1991-04       Impact factor: 10.122

3.  A crossover study on lipid and weight changes associated with olanzapine and risperidone.

Authors:  Kuan-Pin Su; Po-Lun Wu; Carmine M Pariante
Journal:  Psychopharmacology (Berl)       Date:  2005-10-21       Impact factor: 4.530

Review 4.  Obesity and lipids.

Authors:  Wendy M Miller; Katherine E Nori-Janosz; Martin Lillystone; Jose Yanez; Peter A McCullough
Journal:  Curr Cardiol Rep       Date:  2005-11       Impact factor: 2.931

Review 5.  Is there a rational use for n-3 fatty acids (fish oils) in clinical medicine?

Authors:  A Nordøy
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

6.  Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome.

Authors:  György Paragh; Ildikó Seres; Mariann Harangi; Annamária Erdei; Mária Audikovszky; Lóránd Debreczeni; Anna Kovácsay; László Illyés; Gyula Pados
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

7.  Contributions of de novo synthesis of fatty acids to total VLDL-triglyceride secretion during prolonged hyperglycemia/hyperinsulinemia in normal man.

Authors:  A Aarsland; D Chinkes; R R Wolfe
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

8.  Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients.

Authors:  Vasilios G Athyros; Anna I Kakafika; Athanasios A Papageorgiou; Konstantinos Tziomalos; Athanasios Skaperdas; Efstathios Pagourelias; Athina Pirpasopoulou; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Lipids       Date:  2007-08-23       Impact factor: 1.880

9.  Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study.

Authors:  A Fontbonne; E Eschwège; F Cambien; J L Richard; P Ducimetière; N Thibult; J M Warnet; J R Claude; G E Rosselin
Journal:  Diabetologia       Date:  1989-05       Impact factor: 10.122

10.  The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis.

Authors:  K Tsutsumi; Y Inoue; A Shima; K Iwasaki; M Kawamura; T Murase
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.